Skip to main content
. 2022 Jun 15;12(5):682–691. doi: 10.21037/hbsn-21-558

Table 2. Modified Igls classification after islet auto-transplantation.

Classification HbA1c SHE (per year) Insulin dose C-peptide
(A) Igls
   Optimal <6.5% None None > Baseline
   Good <7% None <50% Baseline > Baseline
   Marginal Baseline < Baseline ≥50% Baseline > Baseline
   Failed Baseline Baseline Baseline Baseline
(B) Minnesota Auto-Igls *
   Optimal <6.5% None None >0.5 ng/mL (≥0.2 ng/mL)
   Good <7% None <0.5 units/kg/day >0.5 ng/mL (≥0.2 ng/mL)
   Marginal ≥7% ≥1 ≥0.5 units/kg/day >0.5 ng/mL (≥0.2 ng/mL)
   Failed ≤0.5 ng/mL (≥0.2 ng/mL)
(C) Leicester Auto-Igls *
   Good None (up to 5 years) >0.5 ng/mL (≥0.2 ng/mL)
   Partial <20 units/day >0.5 ng/mL (≥0.2 ng/mL)
   Poor 20–40 units/day (within 5 years) >0.5 ng/mL (≥0.2 ng/mL)
   Failed ≤0.5 ng/mL

*, C-peptide stimulated (fasting). (A) Original Igls classification; (B) Minnesota Modified Auto-Igls classification; (C) Leicester Modified Auto-Igls classification. HbA1c, haemoglobin A1c; SHE, severe hypoglycaemia episodes.